Sie sind auf Seite 1von 22


Ori Hadomi, CEO


June 2017

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and other securities laws. Forward-looking statements are not historical facts, and are based upon
managements current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.
Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that
managements expectations, beliefs and projections will be achieved and actual results may differ materially from
what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks
and uncertainties that could cause actual performance or results to differ materially from those expressed in the
forward-looking statements, including risks detailed in Mazor Robotics Ltd.s (Mazor Robotics or the Company)
annual reports on Form 20-F filed with the U.S. Securities and Exchange Commission. The following solution is not
yet cleared for use: ArcAid device.

Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation
to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in
assumptions or changes in other factors affecting forward-looking information except to the extent required by
applicable securities laws. If the Company does update one or more forward-looking statements, no inference should
be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking

mazo rro b o 'cs. co m 2

From Vision to Experienced Market Leader

230 employees, worldwide Core technology evolu'on with three

genera6ons of commercial products

Suppor'ng and serving

150+ installa6ons and 40+ peer-reviewed ar'cles and
spine program globally strong evidence of improved
pa'ent outcomes

23,000+ Pa6ents , 100s of

surgeons, wide spectrum of Surgical technique used for
procedures precise placement of
160,000+ implants
mazo rro b o 'cs. co m 3
Growing Penetration of US Hospital Market

US Penetra6on
(end of Q1/17)
X XX X X 104 Systems Installed
in the US
X 43 Mazor X Orders
since Launch
X 6 Customers with
X mul'ple system
X Bioskills Lab X orders
X Mazor X
X 16 systems ordered by
HCA hospital chain
mazo rro b o 'cs. co m 4
Hospital, Geographic and Procedure Diversity

Procedure Types Hospital Types (US) Geographical Distribu6on

5% 10%
9% 24%

61% 19%
64% 12%

Revision Deformi'es Degenera've Academic Specialty Community ASC APAC Europe US

mazo rro b o 'cs. co m

Innovative Core Technology
Foundation of Mazors Portfolio of Systems

Image modality Op6cal
SoZware Bone Robo6c Tool Data
Process- Image Navig-
Tools Mount Guidance Develop- Analy6cs
ing Registr- a6on

mazo rro b o 'cs. co m 6

Mazor X
Predictability, Safety and Efficiency through Innovation

1. Pre Op Analy6cs 2. Guided Execu6on 3. Intra Op Verica6on

mazo rro b o 'cs. co m 7

Mazor X and Renaissance
Predictability, Safety and Efficiency through Innovation

1. Pre Op Analy6cs 2. Guided Execu6on 3. Intra Op Verica6on

mazo rro b o 'cs. co m 8

Mazor X
Predictability, Safety and Efficiency through Innovation

1. Pre Op Analy6cs 2. Guided Execu6on 3. Intra Op Verica6on

mazo rro b o 'cs. co m 9

Evidence-based Medicine
From Accuracy to Outcomes

Consistent Accuracy with Improved Outcomes Proven Reduction in Complications and Revisions (1)
Free-Hand Mazor

5.2% 5.8%

Complica'ons Revisions

Dr. K. Poelstra , Orthopedist, Des6n, FL Proven Reduction in Exposure to Radiation (2)

[With Mazor ]Weve put in more than 3,000 screws and

had zero failures. I do evidence-based surgery, and weve
actually shown that the risk of running into any kind of
complicaAon is reduced three fold compared to minimally
invasive cases using freehand MIS without the robot,
and re-operaAon rates are also three- to four fold less.
1.Based on published data: Cannestra, e-poster NASS 2014; Kantelhardt, ESJ 2011; Ringel, ESJ 2012, Roser, 2013.
2.Freehand represents the average fluoro radiation exposure during a freehand operation as a baseline for comparison to Renaissance only.
mazo rro b o 'cs. co m 10
Accelerated Clinical Utilization
Serving more patients

Annual Procedures US Average Procedures per Ac6ve System

Average Number of Procedures per System
2014 2015 2016

Dr. Dennis Devito, MD, Atlanta, Georgia

I nd it provides beTer pa'ent care through enhancement of the surgeon capabili'es and it also makes my
surgical work easier.

mazo rro b o 'cs. co m 11

Sales Strategy
Building Momentum and Awareness



mazo rro b o 'cs. co m 12

Current Business Model
Three Sources

Capital Sales (List Prices) Per Case Revenue Per System Revenue

Disposable Kits: List Price $1,500 Annual Service revenues:

Mazor X: $1,100K
10% of system price
Renaissance: $ 650K Synergy fee revenue:* ~$1,000
(*) per procedure with partner implant

mazo rro b o 'cs. co m 13

Mazor and Medtronic Strategic Agreements
Cooperation Successfully Established

Marketing Professional Education Sales

Joint workstreams and ~150 surgeons participated in 43 Mazor X orders since

global workshops focusing Mazor X training labs commercial launch (Q4/16)
on messaging, targeting and
positioning Pipeline broadened

mazo rro b o 'cs. co m 14

Mazor X - Core of the Surgical Assurance Platform
Short Term Roadmap
*Not yet approved for use

Medtronic Mazor X Scan & Plan
Co-Development (Update)

2018* ArcAid
Futuris'c rod bending 2017
for Mazor X-Align plan Mazor X SIJ
Mazor X Lateral

2017 2018
Medtronic implant planning Mazor X Align
mazo rro b o 'cs. co m 15
Medtronic and Mazor Commercial Integration
Assuming Phase II (by Q1/18)

Investment Sales Mazor X Systems Strategic

1st and 2nd tranches Medtronic assumes full Mul6-year commitment Development
complete: $32M (~8%) global responsibility for to sales quotas at Commitment
product, clinical and distributor pricing
3rd Tranche investment sales support Spine non-compete
at Mazors discre6on
(up to 15%)


Expenses of Systems integrated
(2016 Actual: $34M) procedures
mazo rro b o 'cs. co m 16
A Path to Profitability

2016 ~ 2020*
Revenue 100% 100%

Gross Margin 70.5% ~70%

Operating costs 101% ~50%

EBITDA (31%) ~25%

* Assuming entering the phase 2 of Medtronic agreement.

NOLs NOLs at Israeli parent company of ~$90M
mazo rro b o 'cs. co m 17
Exploring Additional Growth Drivers
Leveraging Technology to Make Surgery Predictable and Safe

New Go-to-Market Leverage Soeware Leverage Robo'cs

Strategy for the Renaissance to create OR HUB Non-Spine and Future
mazo rro b o 'cs. co m 18
Financial Results

Income Statement

Year Ended December 31, 3 Months Ended March 31,

($ in thousands) 2016 2015 2017 2016
Revenue $36,379 $26,096 $11,719 $6,419
Cost of sales $10,330 $5,827 $4,149 $1,654
Gross Profit $26,049 $20,269 $7,570 $4,765
% margin 72% 78% 65% 74%

Operating Expenses
Research and development $5,736 $6,324 $1,792 $2,131
Selling and marketing $33,637 $24,947 $9,893 $6,873
General and administrative $5,697 $4,305 $1,571 $983
Total operating expenses $45,070 $35,576 $13,256 $9,987
% of revenue 124% 136% 113% 156%

Loss from operations ($19,021) ($15,307) ($5,686) ($5,222)

Net loss ($18,668) ($15,385) ($5,232) ($5,112)

mazo rro b o 'cs. co m 19
Balance Sheet

Consolidated Statements of Financial Position

As of March 31, As of December 31,

($ in thousands) 2017 2016
Assets (Unaudited) (Audited)
Cash and Cash equivalent $25,896 $14,954
Short-term investments $32,654 $37,862
Trade receivables $3,076 $8,225
Other accounts receivable $2,109 $1,728
Inventory $5,777 $4,715
Total current assets $69,512 $67,484

Total non-current assets $12,567 $15,241

Total Assets $82,079 $82,725

Current liabilities $18,191 $17,511

Total non-current liabilities $403 $325

Equity $63,485 $64,889

Total liabilities and Equity $82,079 $82,725

mazo rro b o 'cs. co m 20


Surgery Assurance Expanded Co-

Market Access Platform Developed Product

Accelerating growth

mazo rro b o 'cs. co m 21